Dietary polyphenols may suppress growth of adipose tissue through
their antiangiogenic activity and by modulating adipocyte metabolism
curcumin, the major polyphenol in turmeric spice
curcumin suppression of angiogenesis in adipose tissue together with its effect on lipid metabolism in adipocytes may contribute to
lower body fat and body weight gain
This review evaluates the effects of tocotrienols on the risk factors of metabolic syndrome using data from human, animal and in vitro studies. Tocotrienols improved lipid profiles and reduced atherosclerotic lesions, decreased blood glucose and glycated hemoglobin concentrations, normalized blood pressure, and inhibited adipogenesis.
High aromatase activity and estradiol production in men was found to be associated with elevated total cholesterol, LDL, TC:HDL, and triglycerides. No association was found with Testosterone or SHBG. The 111 men in this study had "stable CAD"
Small study of 2 men with type II diabetes finds fasting glucose levels negatively correlate with total and free Testosterone levels, HgbA1c negatively correlated with SHBG only, total cholesterol and LDL negatively correlated with SHBG and total testosterone. The prevalence of type II diabetes was higher with low free Testosterone than total Testosterone, but both were statistically significant.
Lower LDL levels associated with increased risk of Parkinson's disease. LDL levels < 113 were associated with a 3.5 fold increase in Parkinson's disease compared to LDL of 138.
Study finds 50 mg of DHEA improves insulin sensitivity in Hypoadrenal women. The authors also found and increase in DHEAS, bioavailable T, androstenedione, and a reduced SHBG, insulin, and glucagon.
Spice it up for cholesterol. Study finds small, but significant, improvement in in HDL, LDL, and triglycerides with daily curcumin in those with metabolic syndrome.
The prevalence of hypogonadism (often defined as serum testosterone < 300 ng dl−1 ) ranges from 6% [10] to as high as 38%
The process of BPH, however, continues as men age and despite the fact their serum testosterone decreases
Liu et al. [12] demonstrated that in a group of older males (mean age 59.8 years) that there was not a significant correlation of serum testosterone levels (total, free or bioavailable) with either prostate volume or International Prostate Symptom Score (IPSS)
in eugonadal men, studies have demonstrated that the prostate can increase in volume by approximately 12%
There seems to be little doubt that the treatment with testosterone of a young hypogonadal male leads to significant growth of the prostate
Behre et al. [22] demonstrated increased prostate volume and prostate-specific antigen (PSA) levels in hypogonadal men
Most studies, however, have shown no effect of exogenous androgens on PSA or prostate volume for older hypogonadal males
They argue that the prostate is relatively insensitive to changes in androgen concentration at normal levels or in mild hypogonadism because the AR is saturated by androgens and therefore maximal androgen-AR binding is achieved. Conversely, the prostate is very sensitive to changes in androgen levels when testosterone is low
saturation model
visceral obesity (one of the most significant components of metabolic syndrome) is associated with prostate volume and influences prostate growth during TRT.
This hypothesis of inflammation induced LUTS is also argued to be a mechanism for improvement of LUTS with PDE5I
The concept, therefore, that treatment with TRT of hypogonadal males with metabolic syndrome might lead to improvement/stabilization of their LUTS, appears to be confirmed in recent work by Francomano et al.
There was also an improvement in components of the patient's metabolic syndrome (such as BMI, waist circumference, hemoglobin A1c [HbA1c], insulin sensitivity, and lipid profile) as well as inflammatory markers and C-reactive protein.
They concluded that TRT was safe in this group of men, and hypothesize that TRT mitigates the pro-inflammatory factors associated with metabolic syndrome.
Authors review the literature behind Testosterone and BPH. The authors highlight the 4 proposed theories behind BPH: Testosterone, Estrogen, inflammation, and metabolic.
The conclusion is mixed: pointing out that no high level of evidence exists on either side of the debate of Testosterone and BPH.
Data review finds NAC improves pregnancy rates and ovulation rates in women with PCOS against placebo. Meta-analysis revealed limited studies on the topic. When compared to metformin, there was no difference found. Though, one wonders if attacking insulin resistance through proper diet and additional neutraceutical approach would negate that. The reason? NAC and metformin are working in different biochemical pathways. The authors here seem to not realize this. It appears that they think NAC and metormin are both working in the same manner, but they don't. The fact that there is still benefit found compared to placebo, despited the authors lack of understanding of what NAC is and does is a positive.